

Corp. Office : SM House, 11 Sahakar Road, Vile Parle (East), Mumbai - 400 057, Tel.: (+91-22) 6726 1000,
Fax: (+91-22) 6726 1067, Email : info@guficbio.com, Website: www.gufic.com

103/LG/SE/APR/2026/GBSL

April 29, 2026

To,
BSE Limited,
Phiroze Jeejeebhoy Towers,
Dalal Street, Fort, Mumbai – 400 001
Scrip Code: 509079

To,
National Stock Exchange of India Limited,
Exchange Plaza, Bandra Kurla Complex,
Bandra (E), Mumbai – 400 051
Scrip Symbol: GUFICBIO

Sub.: Update on further investment in Selvax Pty Ltd. (“Selvax”)

Dear Sir/Madam,

In furtherance to our earlier intimation dated February 13, 2026, vide letter ref. no. 25/LG/SE/FEB/2026/GBSL regarding further investment in M/s. Selvax Pty Ltd. (“Selvax”), an Australian Company and pursuant to Regulation 30 read with Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (‘SEBI Listing Regulations’), we wish to inform that the Company has made further investment of USD 50,000/- in Selvax by way of subscription to 3,78,350 Ordinary shares at AUD 20 cents per share on April 28, 2026.

The details as required under Regulation 30 of SEBI Listing Regulations read with SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/1/3762/2026 dated January 30, 2026 is as under:

Sr. No.	Particulars	Details
1.	Name of the target entity, details in brief such as size, turnover etc.	Selvax Pty Limited (“Selvax”) is an Australian Proprietary Company, Limited by Shares, engaged in health and allied services and situated in Western Australia. It’s a Bio-technology company, which is developing a novel immunology based treatment for large solid tumours. The technology is fully owned by Selvax and it is envisaged that successful development of the

Regd. Off. : 37, First Floor, Kamala Bhavan II, S. Nityanand Road, Andheri (East), Mumbai - 400 069

Plants : Unit No. 1: N. H. No. 8, Near grid, Kabilpore - 396424, Navsari, Gujarat (INDIA)

Unit No. 2: Survey No. 171, N. H. No. 8, Near grid, Kabilpore - 396424, Navsari, Gujarat (INDIA)

Plot No. 48, Smart Industrial Park, Near Natrip, Pithampur, District Dhar - 454775, Madhya Pradesh
703, Belgaum Industrial Estate, Udhyambag, Belgaum - 590008, Karnataka

		<p>technology will provide novel cancer treatments for animals and humans.</p> <p>Highlights of the benefits from Immunotherapy application:</p> <ul style="list-style-type: none"> a) Better outcome and lower toxicity should result in an improved quality of life for the cancer patient; b) Potentially able to overcome increased drug resistance seen in the larger tumours treated with individual immunotherapy (or chemotherapy) agents; c) Specifically targeting tumour site means lower doses and less side effects; d) Treatment in one location leads to a whole- immune body response that can clear other un-treated tumours, so this therapy can potentially be applied to patients with metastatic cancer; e) Potentially suitable for treating a range of solid tumour in humans and dogs including sarcomas, lung cancer, pancreatic, skin, breast, and colorectal cancer; and f) The induction of long term-immunological memory to protect patients against cancer recurrence. <p>The total Issued Share Capital of Selvax as on June 30, 2025 is AUD 52,85,176/-.</p>
2.	Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group / group companies have any interest in	<p>No, this acquisition does not fall within the purview of related party transactions.</p> <p>Further, the promoter / promoter group / group companies have no interest in Selvax whose</p>

Corp. Office : SM House, 11 Sahakar Road, Vile Parle (East), Mumbai - 400 057, Tel.: (+91-22) 6726 1000,
Fax: (+91-22) 6726 1067, Email : info@guficbio.com, Website: www.gufic.com

	the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at “arm’s length”	equity shares are being acquired by the Company.
3.	Industry to which the entity being acquired belongs	It is a biopharma research and development company.
4.	Objects and impact of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity);	The acquisition of equity shares in Selvax is a strategic arrangement for the development of immunotherapy solutions in oncology and is intended to enable the Company to diversify into the healthcare and biotechnology sector and participate in the development of immunology-based treatments for large solid tumours. The investment aligns with the Company’s long-term strategy of strategic diversification and value creation, providing access to proprietary technology, research capabilities and potential commercial opportunities in both human and veterinary oncology and is expected to generate sustainable long-term benefits for the Company and its stakeholders once the therapy is medically commercialised.
5.	Brief details of any governmental or regulatory approvals required for the acquisition	Not Applicable
6.	Indicative time period for completion of the acquisition	Transaction Completed
7.	Nature of consideration - whether cash consideration or share swap or any other form and details of the same	Cash consideration

Regd. Off. : 37, First Floor, Kamala Bhavan II, S. Nityanand Road, Andheri (East), Mumbai - 400 069

Plants : Unit No. 1: N. H. No. 8, Near grid, Kabilpore - 396424, Navsari, Gujarat (INDIA)

Unit No. 2: Survey No. 171, N. H. No. 8, Near grid, Kabilpore - 396424, Navsari, Gujarat (INDIA)

Plot No. 48, Smart Industrial Park, Near Natrip, Pithampur, District Dhar - 454775, Madhya Pradesh
703, Belgaum Industrial Estate, Udhyambag, Belgaum - 590008, Karnataka

Corp. Office : SM House, 11 Sahakar Road, Vile Parle (East), Mumbai - 400 057, Tel.: (+91-22) 6726 1000,
Fax: (+91-22) 6726 1067, Email : info@guficbio.com, Website: www.gufic.com

8.	Cost of acquisition and/or the price at which the shares are acquired;	378,350 Ordinary shares at AUD 20 cents per share. The total cost of subscription of the said shares amounts to USD 50,000/-.
9.	Percentage of shareholding / control acquired and / or number of shares acquired	Total no. of Ordinary Shares held after Post-Acquisition – 16,85,350 shares
10.	Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief)	<p>Brief Background: Selvax was incorporated on August 14, 1987. It is a biotechnology Company, which is developing a novel immunology based treatment for large solid tumours and the technology is fully owned by the Company and it is envisaged that successful development of the technology will provide novel cancer treatment for animals and humans.</p> <p>Country in which the acquired entity has presence: Australia</p> <p>Total Income of last 3 years: (financial year commencing on July 01 to June 30)</p> <p>For year ended June 30, 2025: AUD 356,972</p> <p>For year ended June 30, 2024: AUD 248,817</p> <p>For year ended June 30, 2023: AUD 220,435.25</p>

Kindly take the same on record.

Thanking You,

For Gufic Biosciences Limited

Ami Shah
Company Secretary & Compliance Officer
Membership No. A39579

Regd. Off. : 37, First Floor, Kamala Bhavan II, S. Nityanand Road, Andheri (East), Mumbai - 400 069

Plants : Unit No. 1: N. H. No. 8, Near grid, Kabilpore - 396424, Navsari, Gujarat (INDIA)

Unit No. 2: Survey No. 171, N. H. No. 8, Near grid, Kabilpore - 396424, Navsari, Gujarat (INDIA)

Plot No. 48, Smart Industrial Park, Near Natrip, Pithampur, District Dhar - 454775, Madhya Pradesh
703, Belgaum Industrial Estate, Udhyambag, Belgaum - 590008, Karnataka